일회용 바이오리액터 시장 : 제품별, 유형별, 분자 유형별, 세포 유형별, 용도별, 처리 모드별, 최종사용자별, 지역별 - 세계 예측(-2031년)

The single-use bioreactors market is projected to reach USD 9.58 billion by 2031 from an estimated USD 5.43 billion in 2026, at a CAGR of 12.0% during the forecast period of 2026 to 2031. Market growth is primarily supported by expanding biologics and biosimilar production, rising vaccine manufacturing, increasing outsourcing to CDMOs, and greater adoption of flexible bioprocessing technologies.

The growing use of single-use systems in monoclonal antibody, recombinant protein, viral vector, and cell & gene therapy manufacturing is further accelerating demand. Their lower capital requirements, reduced cleaning validation, faster product changeovers, and suitability for multiproduct facilities are expected to support market expansion.

By application, the bioproduction segment accounted for the largest share of the market in 2025.

In 2025, the bioproduction segment accounted for the largest share of the global single-use bioreactors market. These systems are extensively used for the commercial and clinical production of monoclonal antibodies, vaccines, recombinant proteins, biosimilars, viral vectors, and other biologics. The segment's leading position is supported by increasing demand for biologics, expansion of global manufacturing capacity, and growing adoption of scalable single-use platforms across pharmaceutical and biotechnology companies and CDMOs. Their ability to reduce contamination risks, shorten turnaround times, and support batch, fed-batch, and perfusion processes further strengthens their use in bioproduction applications.

The monoclonal antibodies segment accounted for a major share of the single-use bioreactors market in 2025.

The single-use bioreactors market is categorized by molecule type into monoclonal antibodies, vaccines, cell & gene therapy, and therapeutic proteins & peptides. The monoclonal antibodies segment accounted for the largest market share in 2025, supported by the substantial number of approved products, extensive development pipelines, and continued expansion of commercial manufacturing capacity. Monoclonal antibody production requires scalable and tightly controlled mammalian cell culture processes, creating sustained demand for stirred-tank single-use bioreactors, bags, assemblies, sensors, and fluid-management components. Their suitability for batch, fed-batch, and intensified processing further supports adoption across pharmaceutical and biotechnology companies and CDMOs.

The Asia Pacific region is expected to experience the highest CAGR in the single-use bioreactors market from 2026 to 2031.

The single-use bioreactors market is divided into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Asia Pacific is expected to register the fastest growth during the forecast period, driven by expanding biologics and biosimilar production, increasing vaccine manufacturing, rising CDMO capacity, and greater investment in domestic biopharmaceutical infrastructure. China, India, Japan, South Korea, and Australia are strengthening their upstream processing capabilities through new facilities, capacity additions, and wider adoption of modular and flexible production technologies. Government support for local manufacturing and the growth of cell & gene therapy activity are further accelerating regional demand.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side (80%) and Demand Side (20%)
• By Designation: Managers (45%), CXOs & Directors (30%), and Executives (25%)
• By Region: North America (40%), Europe (25%), Asia Pacific (25%), Latin America (5%), and the Middle East & Africa (5%)

Sartorius AG (Germany), Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Avantor, Inc. (US), Repligen Corporation (US), Getinge AB (Sweden), Eppendorf SE (Germany), Parker Hannifin Corporation (US), Entegris (US), Saint-Gobain (France), Corning Incorporated (US), Lonza (Switzerland), TECNIC Process Equipment Manufacturing, S.L. (Spain), ZACROS Corporation (Japan), Adolf Kuhner AG (Switzerland), OmniBRx Biotechnologies Pvt Ltd. (India), New Horizon Biotechnology, Inc. (US), PBS Biotech, Inc. (US), bbi-biotech GmbH (Germany), ABEC, Inc. (US), Esco Lifesciences Group (US), Distek, Inc. (US), SATAKE MultiMix Corporation (Japan), Cell Culture Company, LLC (US), MicroDigital Co., Ltd. (South Korea), BIONET (Spain), Meissner Filtration Products, Inc. (US), Solida Biotech GmbH (Germany), G&G Technologies, Inc. (US), PharmNXT Biotech (India), and Tofflon Life Science Co., Ltd. (China) are some of the key companies offering single-use bioreactors solutions.

Research Coverage

This research report categorizes the single-use bioreactors market by product (single-use bioreactor systems, single-use bags, single-use assemblies, and other products), type (stirred-tank single-use bioreactors, wave-induced single-use bioreactors, fixed-bed single-use bioreactors, bubble-column single-use bioreactors, and other single-use bioreactors), cell type (mammalian cells, bacterial cells, yeast cells, and other cells), molecule type (monoclonal antibodies, vaccines, cell & gene therapy, and therapeutic proteins & peptides), process mode (fed-batch, batch, and perfusion/continuous), application (bioproduction, process development, and research & development), end user (pharmaceutical and biotechnology companies, CROs & CMOs, and academic & research institutes), and region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa).

The scope of the report provides detailed information on major factors such as drivers, challenges, opportunities, and restraints that influence the growth of the single-use bioreactors market. A comprehensive analysis of key industry players has been conducted to provide insights into their business overviews, product portfolios, and key strategies, including collaborations, partnerships, expansions, agreements, acquisitions, and recent developments in the single-use bioreactors market.

Key Benefits of Buying the Report

This report offers a comprehensive overview of the single-use bioreactors market. It aims to assess the market size and future growth opportunities across various segments. The report also features an in-depth competitive analysis of the major market players, including their company profiles, recent developments, and key market strategies

The report provides insights into the following pointers:

• Analysis of key drivers (rising adoption of flexible sub platforms among CDMOs, CMOs, and SMEs, operational advantages over conventional bioreactors, reduced upfront capital investment, reduced water and energy consumption, and expansion of biologics and biosimilar manufacturing demand), restraints (concerns related to extractables and leachables, regulatory and compliance requirements for SUB implementation, and impact of PFAS restrictions on product development), opportunities (untapped growth potential in emerging biomanufacturing economies and shift toward hybrid biomanufacturing), and challenges (lack of standardization, waste disposal burden and sustainability pressure, and risk of SU bag leakage and integrity failure) influencing the growth of the market.
• Product Development/Innovation: Detailed insights on newly launched products of the single-use bioreactors market.
• Market Development: Comprehensive information about lucrative markets; the report analyzes the market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the single-use bioreactors market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players such as Sartorius AG (Germany), Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Avantor, Inc. (US), Repligen Corporation (US), Getinge AB (Sweden), Eppendorf SE (Germany), Parker Hannifin Corporation (US), Entegris (US), Saint-Gobain (France), Corning Incorporated (US), Lonza (Switzerland), TECNIC Process Equipment Manufacturing, S.L. (Spain), ZACROS Corporation (Japan), Adolf Kuhner AG (Switzerland), OmniBRx Biotechnologies Pvt Ltd. (India), New Horizon Biotechnology, Inc. (US), PBS Biotech, Inc. (US), bbi-biotech GmbH (Germany), ABEC, Inc. (US), Esco Lifesciences Group (US), Distek, Inc. (US), SATAKE MultiMix Corporation (Japan), Cell Culture Company, LLC (US), MicroDigital Co., Ltd. (South Korea), BIONET (Spain), Meissner Filtration Products, Inc. (US), Solida Biotech GmbH (Germany), G&G Technologies, Inc. (US), PharmNXT Biotech (India), and Tofflon Life Science Co., Ltd. (China).

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION & REGIONS COVERED
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

• 2.1 MARKET HIGHLIGHTS & KEY INSIGHTS
• 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
• 2.3 DISRUPTIVE TRENDS IN SINGLE-USE BIOREACTORS MARKET
• 2.4 HIGH-GROWTH SEGMENTS
• 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

• 3.1 GLOBAL SINGLE-USE BIOREACTORS MARKET SNAPSHOT
• 3.2 NORTH AMERICA: SINGLE-USE BIOREACTORS MARKET, BY PRODUCT AND COUNTRY, 2025
• 3.3 SINGLE-USE BIOREACTORS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 3.4 SINGLE-USE BIOREACTORS MARKET SHARE, BY END USER, 2026 VS. 2031 (%)

4 MARKET OVERVIEW

• 4.1 INTRODUCTION
• 4.2 MARKET DYNAMICS
  • 4.2.1 DRIVERS
    • 4.2.1.1 Rising adoption of flexible SUB platforms among CDMOs, CMOs, and SMEs
    • 4.2.1.2 Operational advantages over conventional bioreactors
    • 4.2.1.3 Reduced upfront capital investment
    • 4.2.1.4 Reduced water and energy consumption
    • 4.2.1.5 Expansion of biologics and biosimilar manufacturing demand
  • 4.2.2 RESTRAINTS
    • 4.2.2.1 Concerns related to extractables and leachables
    • 4.2.2.2 Regulatory and compliance requirements for SUB implementation
    • 4.2.2.3 Impact of PFAS restrictions on product development
  • 4.2.3 OPPORTUNITIES
    • 4.2.3.1 Untapped growth potential in emerging biomanufacturing economies
    • 4.2.3.2 Shift towards hybrid biomanufacturing
  • 4.2.4 CHALLENGES
    • 4.2.4.1 Lack of standardization
    • 4.2.4.2 Waste disposal burden and sustainability pressure
    • 4.2.4.3 Risk of SU bag leakage and integrity failure
• 4.3 UNMET NEEDS & WHITE SPACES
• 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
• 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

• 5.1 PORTER'S FIVE FORCES ANALYSIS
  • 5.1.1 BARGAINING POWER OF SUPPLIERS
  • 5.1.2 BARGAINING POWER OF BUYERS
  • 5.1.3 THREAT OF NEW ENTRANTS
  • 5.1.4 THREAT OF SUBSTITUTES
  • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.2 MACROECONOMIC OUTLOOK
  • 5.2.1 INTRODUCTION
  • 5.2.2 GDP TRENDS & FORECAST
  • 5.2.3 TRENDS IN GLOBAL SINGLE-USE BIOREACTORS INDUSTRY
• 5.3 VALUE CHAIN ANALYSIS
• 5.4 ECOSYSTEM ANALYSIS
• 5.5 PRICING ANALYSIS
  • 5.5.1 AVERAGE SELLING PRICE TREND OF KEY SINGLE-USE BIOREACTOR PRODUCTS, BY KEY PLAYER, 2023-2025
  • 5.5.2 AVERAGE SELLING PRICE TREND OF KEY SINGLE-USE BIOREACTOR PRODUCTS, BY REGION, 2023-2025
• 5.6 TRADE ANALYSIS
  • 5.6.1 IMPORT SCENARIO (HS CODE 841989)
  • 5.6.2 EXPORT SCENARIO (HS CODE 841989)
• 5.7 KEY CONFERENCES & EVENTS, 2026-2027
• 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.9 INVESTMENT & FUNDING SCENARIO
  • 5.9.1 VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE
• 5.10 IMPACT OF 2025 US TARIFFS ON SINGLE-USE BIOREACTORS MARKET
  • 5.10.1 INTRODUCTION
  • 5.10.2 KEY TARIFF RATES
  • 5.10.3 PRICE IMPACT ANALYSIS
  • 5.10.4 IMPACT ON COUNTRIES/REGIONS
    • 5.10.4.1 US
    • 5.10.4.2 Europe
    • 5.10.4.3 Asia Pacific
  • 5.10.5 IMPACT ON END-USE INDUSTRIES
    • 5.10.5.1 Pharmaceutical & biotechnology companies
    • 5.10.5.2 CROs & CMOs
    • 5.10.5.3 Academic & research institutes

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, AND INNOVATIONS

• 6.1 TECHNOLOGY ANALYSIS
  • 6.1.1 KEY EMERGING TECHNOLOGIES
    • 6.1.1.1 Fermentation
    • 6.1.1.2 Continuous bioprocessing
    • 6.1.1.3 3D cell culture
  • 6.1.2 COMPLEMENTARY TECHNOLOGIES
    • 6.1.2.1 Automation & control
    • 6.1.2.2 Data analytics & machine learning
  • 6.1.3 ADJACENT TECHNOLOGIES
    • 6.1.3.1 Filtration
    • 6.1.3.2 Cell separation
• 6.2 TECHNOLOGY/PRODUCT ROADMAP
• 6.3 PATENT ANALYSIS
  • 6.3.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR SINGLE-USE BIOREACTOR PATENTS
• 6.4 FUTURE APPLICATIONS
• 6.5 IMPACT OF AI/GEN AI ON SINGLE-USE BIOREACTORS MARKET
  • 6.5.1 BEST PRACTICES IN SINGLE-USE BIOREACTORS WORKFLOW
  • 6.5.2 CASE STUDIES OF AI IMPLEMENTATION IN SINGLE-USE BIOREACTORS MARKET
  • 6.5.3 INTERCONNECTED ADJACENT ECOSYSTEMS & IMPACT ON MARKET PLAYERS
  • 6.5.4 CLIENTS' READINESS TO ADOPT GENERATIVE AI IN SINGLE-USE BIOREACTORS MARKET

7 SUSTAINABILITY & REGULATORY LANDSCAPE

• 7.1 REGIONAL REGULATIONS & COMPLIANCE
  • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 7.1.2 REGULATORY FRAMEWORK
    • 7.1.2.1 North America
    • 7.1.2.2 Europe
    • 7.1.2.3 Asia Pacific
    • 7.1.2.4 Rest of the World
  • 7.1.3 INDUSTRY STANDARDS
• 7.2 SUSTAINABILITY INITIATIVES
• 7.3 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES
• 7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

• 8.1 DECISION-MAKING PROCESS
• 8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
  • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 8.2.2 KEY BUYING CRITERIA, BY END USER
• 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
• 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
• 8.5 MARKET PROFITABILITY

9 SINGLE-USE BIOREACTORS MARKET, BY PRODUCT

• 9.1 INTRODUCTION
• 9.2 SINGLE-USE BIOREACTOR SYSTEMS
  • 9.2.1 <=10 L BIOREACTORS
    • 9.2.1.1 High-throughput process development and scale-down studies to support market growth
  • 9.2.2 11-100 L BIOREACTORS
    • 9.2.2.1 Increasing pilot-scale and clinical manufacturing to support market growth
  • 9.2.3 101-500 L BIOREACTORS
    • 9.2.3.1 Flexible scale-up from clinical to early commercial production to propel market growth
  • 9.2.4 501-1,500 L BIOREACTORS
    • 9.2.4.1 Expanding late-stage and commercial biologics capacity to support market growth
  • 9.2.5 >1,500 L BIOREACTORS
    • 9.2.5.1 Large-scale single-use commercialization to strengthen market position
• 9.3 SINGLE-USE BAGS
  • 9.3.1 2D SINGLE-USE BAGS
    • 9.3.1.1 Low-volume flexibility and expanding cell therapy applications to support market growth
  • 9.3.2 3D SINGLE-USE BAGS
    • 9.3.2.1 Large-volume biologics production to support market growth
• 9.4 SINGLE-USE ASSEMBLIES
  • 9.4.1 INCREASING ADOPTION OF CLOSED FLUID PATHS TO SUPPORT MARKET GROWTH
• 9.5 OTHER PRODUCTS

10 SINGLE-USE BIOREACTORS MARKET, BY TYPE

• 10.1 INTRODUCTION
• 10.2 STIRRED-TANK SINGLE-USE BIOREACTORS
  • 10.2.1 BROAD SCALABILITY AND COMPATIBILITY WITH INTENSIFIED CELL CULTURE TO SUPPORT MARKET GROWTH
• 10.3 WAVE-INDUCED SINGLE-USE BIOREACTORS
  • 10.3.1 INCREASING ADOPTION IN CELL THERAPY AND SEED-TRAIN APPLICATIONS TO SUPPORT MARKET GROWTH
• 10.4 FIXED-BED SINGLE-USE BIOREACTORS
  • 10.4.1 HIGH-DENSITY ADHERENT CELL AND VIRAL VECTOR PRODUCTION TO DRIVE FASTEST MARKET GROWTH
• 10.5 BUBBLE-COLUMN SINGLE-USE BIOREACTORS
  • 10.5.1 IMPELLER-FREE MIXING AND EXPANDING MICROBIAL APPLICATIONS TO SUPPORT MARKET GROWTH
• 10.6 OTHER SINGLE-USE BIOREACTORS

11 SINGLE-USE BIOREACTORS MARKET, BY MOLECULE TYPE

• 11.1 INTRODUCTION
• 11.2 MONOCLONAL ANTIBODIES
  • 11.2.1 EXPANDING THERAPEUTIC PIPELINES AND BIOSIMILAR PRODUCTION TO SUPPORT SEGMENT DOMINANCE
• 11.3 VACCINES
  • 11.3.1 EXPANDING VACCINE PIPELINES AND FLEXIBLE MANUFACTURING REQUIREMENTS TO SUPPORT MARKET GROWTH
• 11.4 CELL & GENE THERAPY
  • 11.4.1 EXPANDING ADVANCED THERAPY PIPELINES AND MANUFACTURING INVESTMENTS TO SUPPORT MARKET GROWTH
• 11.5 THERAPEUTIC PROTEINS & PEPTIDES
  • 11.5.1 INCREASING DEMAND FOR RECOMBINANT PROTEINS AND PEPTIDE THERAPEUTICS TO SUPPORT MARKET GROWTH

12 SINGLE-USE BIOREACTORS MARKET, BY CELL TYPE

• 12.1 INTRODUCTION
• 12.2 MAMMALIAN CELLS
  • 12.2.1 HIGH DEMAND FOR COMPLEX BIOLOGICS TO SUPPORT SEGMENT DOMINANCE
• 12.3 BACTERIAL CELLS
  • 12.3.1 EXPANDING PLASMID DNA AND RECOMBINANT PROTEIN PRODUCTION TO SUPPORT MARKET GROWTH
• 12.4 YEAST CELLS
  • 12.4.1 INCREASING USE IN RECOMBINANT PROTEIN AND VACCINE PRODUCTION TO SUPPORT MARKET GROWTH
• 12.5 OTHER CELLS

13 SINGLE-USE BIOREACTORS MARKET, BY APPLICATION

• 13.1 INTRODUCTION
• 13.2 BIOPRODUCTION
  • 13.2.1 COMMERCIAL BIOLOGICS PRODUCTION AND FLEXIBLE MANUFACTURING CAPACITY TO REINFORCE SEGMENT LEADERSHIP
• 13.3 PROCESS DEVELOPMENT
  • 13.3.1 ACCELERATED PROCESS OPTIMIZATION TO DRIVE GROWTH OF PROCESS DEVELOPMENT APPLICATIONS
• 13.4 RESEARCH & DEVELOPMENT
  • 13.4.1 GROWING ADOPTION OF INTENSIFIED BIOPROCESSING TO DRIVE FASTEST GROWTH IN PERFUSION-BASED MANUFACTURING

14 SINGLE-USE BIOREACTORS MARKET, BY PROCESS MODE

• 14.1 INTRODUCTION
• 14.2 FED-BATCH PROCESS MODE
  • 14.2.1 COMMERCIAL BIOLOGICS MANUFACTURING TO CONTINUE TO POSITION FED-BATCH AS LARGEST PROCESS SEGMENT
• 14.3 BATCH PROCESS MODE
  • 14.3.1 PROCESS DEVELOPMENT AND SMALL-SCALE BIOLOGICS PRODUCTION TO SUSTAIN DEMAND FOR BATCH PROCESSING
• 14.4 PERFUSION/CONTINUOUS PROCESS MODE
  • 14.4.1 GROWING ADOPTION OF INTENSIFIED BIOPROCESSING TO DRIVES FASTEST GROWTH IN PERFUSION-BASED MANUFACTURING

15 SINGLE-USE BIOREACTORS MARKET, BY END USER

• 15.1 INTRODUCTION
• 15.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 15.2.1 COMMERCIAL BIOLOGICS PRODUCTION AND FLEXIBLE MANUFACTURING CAPACITY TO REINFORCE SEGMENT LEADERSHIP
• 15.3 CROS & CDMOS
  • 15.3.1 BIOLOGICS OUTSOURCING TO DRIVE GROWTH AMONG CROS AND CMOS
• 15.4 ACADEMIC & RESEARCH INSTITUTES
  • 15.4.1 EXPANDING LIFE SCIENCE RESEARCH TO CONTINUE TO SUPPORT DEMAND FROM ACADEMIC & RESEARCH INSTITUTES

16 SINGLE-USE BIOREACTORS MARKET, BY REGION

• 16.1 INTRODUCTION
• 16.2 NORTH AMERICA
  • 16.2.1 US
    • 16.2.1.1 US to dominate North American market during study period
  • 16.2.2 CANADA
    • 16.2.2.1 Public bio-manufacturing investment and advanced-therapy capacity expansion to support market growth
• 16.3 EUROPE
  • 16.3.1 GERMANY
    • 16.3.1.1 Strong bioprocessing ecosystem and expanding therapeutic pipelines to support market growth
  • 16.3.2 UK
    • 16.3.2.1 Public funding and advanced-therapy manufacturing to support market growth
  • 16.3.3 FRANCE
    • 16.3.3.1 Strong bioprocessing supply base and biopharmaceutical investments to support market growth
  • 16.3.4 ITALY
    • 16.3.4.1 Strong pharmaceutical manufacturing and advanced-therapy capabilities to support market growth
  • 16.3.5 SPAIN
    • 16.3.5.1 Expanding biotechnology R&D and CDMO capacity to support market growth
  • 16.3.6 REST OF EUROPE
• 16.4 ASIA PACIFIC
  • 16.4.1 CHINA
    • 16.4.1.1 Large biologics pipeline and commercial-scale single-use capacity to drive market growth
  • 16.4.2 SOUTH KOREA
    • 16.4.2.1 Large-scale CDMO capacity and export-oriented biopharmaceutical industry to support market growth
  • 16.4.3 JAPAN
    • 16.4.3.1 Biologics pipeline expansion and regenerative medicine commercialization to support market growth
  • 16.4.4 INDIA
    • 16.4.4.1 Export-oriented biopharmaceutical industry and policy support to drive market growth
  • 16.4.5 AUSTRALIA
    • 16.4.5.1 Clinical research funding and advanced-therapy manufacturing to support market growth
  • 16.4.6 REST OF ASIA PACIFIC
• 16.5 LATIN AMERICA
  • 16.5.1 BRAZIL
    • 16.5.1.1 Public bioproduction investment and expanding vaccine capabilities to support market growth
  • 16.5.2 MEXICO
    • 16.5.2.1 Domestic biopharmaceutical capacity expansion to support market growth
  • 16.5.3 REST OF LATIN AMERICA
• 16.6 MIDDLE EAST
  • 16.6.1 GCC COUNTRIES
    • 16.6.1.1 Saudi Arabia
      • 16.6.1.1.1 National biotechnology strategy and commercial biopharma capacity to propel market growth
    • 16.6.1.2 UAE
      • 16.6.1.2.1 Vaccine manufacturing and regulatory ecosystem development to support market growth
    • 16.6.1.3 Rest of GCC countries
  • 16.6.2 REST OF MIDDLE EAST
• 16.7 AFRICA
  • 16.7.1 VACCINE MANUFACTURING LOCALIZATION AND TECHNOLOGY TRANSFER TO SUPPORT MARKET GROWTH

17 COMPETITIVE LANDSCAPE

• 17.1 OVERVIEW
• 17.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 17.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN SINGLE-USE BIOREACTORS MARKET
• 17.3 REVENUE ANALYSIS, 2021-2025
• 17.4 MARKET SHARE ANALYSIS, 2025
• 17.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
  • 17.5.1 STARS
  • 17.5.2 EMERGING LEADERS
  • 17.5.3 PERVASIVE PLAYERS
  • 17.5.4 PARTICIPANTS
  • 17.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
    • 17.5.5.1 Company footprint
    • 17.5.5.2 Region footprint
    • 17.5.5.3 Product footprint
    • 17.5.5.4 Type footprint
    • 17.5.5.5 Application footprint
• 17.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
  • 17.6.1 PROGRESSIVE COMPANIES
  • 17.6.2 RESPONSIVE COMPANIES
  • 17.6.3 DYNAMIC COMPANIES
  • 17.6.4 STARTING BLOCKS
  • 17.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
    • 17.6.5.1 Detailed list of key startups/SMEs
    • 17.6.5.2 Competitive benchmarking of key startups/SMEs
• 17.7 COMPANY VALUATION & FINANCIAL METRICS
  • 17.7.1 FINANCIAL METRICS
  • 17.7.2 COMPANY VALUATION
• 17.8 BRAND/PRODUCT COMPARISON
• 17.9 COMPETITIVE SCENARIO
  • 17.9.1 PRODUCT LAUNCHES
  • 17.9.2 DEALS
  • 17.9.3 EXPANSIONS

18 COMPANY PROFILES

• 18.1 KEY PLAYERS
  • 18.1.1 SARTORIUS AG
    • 18.1.1.1 Business overview
    • 18.1.1.2 Products offered
    • 18.1.1.3 Recent developments
      • 18.1.1.3.1 Product launches
      • 18.1.1.3.2 Deals
      • 18.1.1.3.3 Expansions
    • 18.1.1.4 MnM view
      • 18.1.1.4.1 Key strengths
      • 18.1.1.4.2 Strategic choices
      • 18.1.1.4.3 Weaknesses & competitive threats
  • 18.1.2 DANAHER CORPORATION
    • 18.1.2.1 Business overview
    • 18.1.2.2 Products offered
    • 18.1.2.3 Recent developments
      • 18.1.2.3.1 Product launches
      • 18.1.2.3.2 Deals
      • 18.1.2.3.3 Expansions
    • 18.1.2.4 MnM view
      • 18.1.2.4.1 Right to win
      • 18.1.2.4.2 Strategic choices
      • 18.1.2.4.3 Weaknesses & competitive threats
  • 18.1.3 THERMO FISHER SCIENTIFIC INC.
    • 18.1.3.1 Business overview
    • 18.1.3.2 Products offered
    • 18.1.3.3 Recent developments
      • 18.1.3.3.1 Product launches
      • 18.1.3.3.2 Deals
      • 18.1.3.3.3 Expansions
    • 18.1.3.4 MnM view
      • 18.1.3.4.1 Right to win
      • 18.1.3.4.2 Strategic choices
      • 18.1.3.4.3 Weaknesses & competitive threats
  • 18.1.4 MERCK KGAA
    • 18.1.4.1 Business overview
    • 18.1.4.2 Products offered
    • 18.1.4.3 Recent developments
      • 18.1.4.3.1 Product launches
      • 18.1.4.3.2 Deals
      • 18.1.4.3.3 Expansions
    • 18.1.4.4 MnM view
      • 18.1.4.4.1 Right to win
      • 18.1.4.4.2 Strategic choices
      • 18.1.4.4.3 Weaknesses & competitive threats
  • 18.1.5 AVANTOR, INC.
    • 18.1.5.1 Business overview
    • 18.1.5.2 Products offered
    • 18.1.5.3 Recent developments
      • 18.1.5.3.1 Deals
      • 18.1.5.3.2 Expansions
  • 18.1.6 REPLIGEN CORPORATION
    • 18.1.6.1 Business overview
    • 18.1.6.2 Products offered
    • 18.1.6.3 Recent developments
      • 18.1.6.3.1 Deals
      • 18.1.6.3.2 Expansions
  • 18.1.7 GETINGE AB
    • 18.1.7.1 Business overview
    • 18.1.7.2 Products offered
    • 18.1.7.3 Recent developments
      • 18.1.7.3.1 Product launches
      • 18.1.7.3.2 Deals
      • 18.1.7.3.3 Expansions
  • 18.1.8 EPPENDORF SE
    • 18.1.8.1 Business overview
    • 18.1.8.2 Products offered
    • 18.1.8.3 Recent developments
      • 18.1.8.3.1 Deals
      • 18.1.8.3.2 Expansions
  • 18.1.9 PARKER HANNIFIN CORPORATION
    • 18.1.9.1 Business overview
    • 18.1.9.2 Products offered
  • 18.1.10 ENTEGRIS
    • 18.1.10.1 Business overview
    • 18.1.10.2 Products offered
  • 18.1.11 SAINT-GOBAIN
    • 18.1.11.1 Business overview
    • 18.1.11.2 Products offered
    • 18.1.11.3 Recent developments
      • 18.1.11.3.1 Product launches
      • 18.1.11.3.2 Expansions
  • 18.1.12 CORNING INCORPORATED
    • 18.1.12.1 Business overview
    • 18.1.12.2 Products offered
  • 18.1.13 LONZA
    • 18.1.13.1 Business overview
    • 18.1.13.2 Products offered
    • 18.1.13.3 Recent developments
      • 18.1.13.3.1 Deals
  • 18.1.14 TECNIC PROCESS EQUIPMENT MANUFACTURING, S.L.
    • 18.1.14.1 Business overview
    • 18.1.14.2 Products offered
    • 18.1.14.3 Recent developments
      • 18.1.14.3.1 Product launches
      • 18.1.14.3.2 Expansions
  • 18.1.15 ZACROS CORPORATION
    • 18.1.15.1 Business overview
    • 18.1.15.2 Products offered
• 18.2 OTHER PLAYERS
  • 18.2.1 ADOLF KUHNER AG
  • 18.2.2 OMNIBRX BIOTECHNOLOGIES PVT LTD.
  • 18.2.3 NEW HORIZON BIOTECHNOLOGY, INC.
  • 18.2.4 PBS BIOTECH, INC.
  • 18.2.5 BBI-BIOTECH GMBH
  • 18.2.6 ABEC, INC.
  • 18.2.7 ESCO LIFESCIENCES GROUP
  • 18.2.8 DISTEK, INC.
  • 18.2.9 SATAKE MULTIMIX CORPORATION
  • 18.2.10 CELL CULTURE COMPANY, LLC
  • 18.2.11 MICRODIGITAL CO., LTD.
  • 18.2.12 BIONET
  • 18.2.13 MEISSNER FILTRATION PRODUCTS, INC.
  • 18.2.14 SOLIDA BIOTECH GMBH
  • 18.2.15 G&G TECHNOLOGIES, INC.
  • 18.2.16 PHARMNXT BIOTECH
  • 18.2.17 TOFFLON LIFE SCIENCE CO., LTD.
  • 18.2.18 SHANGHAI LEPURE BIOTECH CO., LTD.

19 RESEARCH METHODOLOGY

• 19.1 RESEARCH DATA
  • 19.1.1 SECONDARY DATA
    • 19.1.1.1 Key secondary sources
    • 19.1.1.2 Key data from secondary research
  • 19.1.2 PRIMARY DATA
    • 19.1.2.1 Key primary participants
    • 19.1.2.2 Breakdown of primary interviews
    • 19.1.2.3 Key data from primary sources
• 19.2 MARKET SIZE ESTIMATION
  • 19.2.1 GLOBAL SINGLE-USE BIOREACTORS MARKET ESTIMATION, 2025
    • 19.2.1.1 Approach 1: Company revenue analysis-based estimation (bottom-up)
    • 19.2.1.2 Approach 2: Primary research
      • 19.2.1.2.1 Key industry insights
    • 19.2.1.3 Approach 3: MnM repository analysis
  • 19.2.2 SEGMENTAL MARKET SIZE ESTIMATION, 2025
• 19.3 MARKET GROWTH RATE PROJECTIONS
• 19.4 DATA TRIANGULATION
• 19.5 RESEARCH ASSUMPTIONS
• 19.6 RESEARCH LIMITATIONS & RISK ASSESSMENT

20 APPENDIX

• 20.1 DISCUSSION GUIDE
• 20.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 20.3 CUSTOMIZATION OPTIONS
• 20.4 RELATED REPORTS
• 20.5 AUTHOR DETAILS